NCT04854980View on ClinicalTrials.gov

Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients

CompletedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

August 3, 2021

Primary Completion Date

March 15, 2022

Study Completion Date

July 23, 2024

Conditions
Covid19Cancer
Interventions
OTHER

Blood Sample

Blood sample, 2- to 5 tea spoon full (between 10 to 25 mL approximately) between 43 to 96 days after first dose of the vaccine.

Trial Locations (1)

14642

University of Rochester, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT04854980 - Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients | Biotech Hunter | Biotech Hunter